EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Werner Kempf, Katrin Pfaltz, Maarten H. Vermeer, Antonio Cozzio, Pablo L. Ortiz-Romero, Martine Bagot, Elise Olsen, Youn H. Kim, Reinhard Dummer, Nicola Pimpinelli, Sean Whittaker, Emmilia Hodak, Lorenzo Cerroni, Emilio Berti, Steve Horwitz, H. Miles Prince, Joan Guitart, Teresa Estrach, José A. Sanches, Madeleine DuvicAnnamari Ranki, Brigitte Dreno, Sonja Ostheeren-Michaelis, Robert Knobler, Gary Wood, Rein Willemze

Research output: Contribution to journalArticle

240 Citations (Scopus)

Abstract

Primary cutaneous CD30 + lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30 + LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30 + LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30 + PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30 + LPDs.

Original languageEnglish (US)
Pages (from-to)4024-4035
Number of pages12
JournalBlood
Volume118
Issue number15
DOIs
StatePublished - Oct 13 2011

Fingerprint

Primary Cutaneous Anaplastic Large Cell Lymphoma
Lymphomatoid Papulosis
T-cells
Lymphoproliferative Disorders
Tumors
Cells
Lymphoma
Skin
Cutaneous T-Cell Lymphoma
Advisory Committees
Multicenter Studies
Neoplasms
Clinical Trials
Organizations
Prospective Studies
Guidelines
Recurrence
Therapeutics
Research

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders : Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. / Kempf, Werner; Pfaltz, Katrin; Vermeer, Maarten H.; Cozzio, Antonio; Ortiz-Romero, Pablo L.; Bagot, Martine; Olsen, Elise; Kim, Youn H.; Dummer, Reinhard; Pimpinelli, Nicola; Whittaker, Sean; Hodak, Emmilia; Cerroni, Lorenzo; Berti, Emilio; Horwitz, Steve; Prince, H. Miles; Guitart, Joan; Estrach, Teresa; Sanches, José A.; Duvic, Madeleine; Ranki, Annamari; Dreno, Brigitte; Ostheeren-Michaelis, Sonja; Knobler, Robert; Wood, Gary; Willemze, Rein.

In: Blood, Vol. 118, No. 15, 13.10.2011, p. 4024-4035.

Research output: Contribution to journalArticle

Kempf, W, Pfaltz, K, Vermeer, MH, Cozzio, A, Ortiz-Romero, PL, Bagot, M, Olsen, E, Kim, YH, Dummer, R, Pimpinelli, N, Whittaker, S, Hodak, E, Cerroni, L, Berti, E, Horwitz, S, Prince, HM, Guitart, J, Estrach, T, Sanches, JA, Duvic, M, Ranki, A, Dreno, B, Ostheeren-Michaelis, S, Knobler, R, Wood, G & Willemze, R 2011, 'EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma', Blood, vol. 118, no. 15, pp. 4024-4035. https://doi.org/10.1182/blood-2011-05-351346
Kempf, Werner ; Pfaltz, Katrin ; Vermeer, Maarten H. ; Cozzio, Antonio ; Ortiz-Romero, Pablo L. ; Bagot, Martine ; Olsen, Elise ; Kim, Youn H. ; Dummer, Reinhard ; Pimpinelli, Nicola ; Whittaker, Sean ; Hodak, Emmilia ; Cerroni, Lorenzo ; Berti, Emilio ; Horwitz, Steve ; Prince, H. Miles ; Guitart, Joan ; Estrach, Teresa ; Sanches, José A. ; Duvic, Madeleine ; Ranki, Annamari ; Dreno, Brigitte ; Ostheeren-Michaelis, Sonja ; Knobler, Robert ; Wood, Gary ; Willemze, Rein. / EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders : Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. In: Blood. 2011 ; Vol. 118, No. 15. pp. 4024-4035.
@article{9ea48c14c695420f9d48a6bd8b5cf943,
title = "EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma",
abstract = "Primary cutaneous CD30 + lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30 + LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30 + LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30 + PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30 + LPDs.",
author = "Werner Kempf and Katrin Pfaltz and Vermeer, {Maarten H.} and Antonio Cozzio and Ortiz-Romero, {Pablo L.} and Martine Bagot and Elise Olsen and Kim, {Youn H.} and Reinhard Dummer and Nicola Pimpinelli and Sean Whittaker and Emmilia Hodak and Lorenzo Cerroni and Emilio Berti and Steve Horwitz and Prince, {H. Miles} and Joan Guitart and Teresa Estrach and Sanches, {Jos{\'e} A.} and Madeleine Duvic and Annamari Ranki and Brigitte Dreno and Sonja Ostheeren-Michaelis and Robert Knobler and Gary Wood and Rein Willemze",
year = "2011",
month = "10",
day = "13",
doi = "10.1182/blood-2011-05-351346",
language = "English (US)",
volume = "118",
pages = "4024--4035",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders

T2 - Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

AU - Kempf, Werner

AU - Pfaltz, Katrin

AU - Vermeer, Maarten H.

AU - Cozzio, Antonio

AU - Ortiz-Romero, Pablo L.

AU - Bagot, Martine

AU - Olsen, Elise

AU - Kim, Youn H.

AU - Dummer, Reinhard

AU - Pimpinelli, Nicola

AU - Whittaker, Sean

AU - Hodak, Emmilia

AU - Cerroni, Lorenzo

AU - Berti, Emilio

AU - Horwitz, Steve

AU - Prince, H. Miles

AU - Guitart, Joan

AU - Estrach, Teresa

AU - Sanches, José A.

AU - Duvic, Madeleine

AU - Ranki, Annamari

AU - Dreno, Brigitte

AU - Ostheeren-Michaelis, Sonja

AU - Knobler, Robert

AU - Wood, Gary

AU - Willemze, Rein

PY - 2011/10/13

Y1 - 2011/10/13

N2 - Primary cutaneous CD30 + lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30 + LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30 + LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30 + PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30 + LPDs.

AB - Primary cutaneous CD30 + lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30 + LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30 + LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30 + PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30 + LPDs.

UR - http://www.scopus.com/inward/record.url?scp=80054119243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054119243&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-05-351346

DO - 10.1182/blood-2011-05-351346

M3 - Article

C2 - 21841159

AN - SCOPUS:80054119243

VL - 118

SP - 4024

EP - 4035

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -